BRAF and colorectal cancer: Specifically for colorectal cancer cell lines, BRAF mutant cell lines display also greater sensitivity to inhibitor WZ4003 compared to BRAF wild type colorectal cancer cell lines (mean IC50: 63.7 μM versus 132 μM), although, due to smaller numbers, this difference did not reach statistical significance (p = 0.08).